Pompili, Cecilia http://orcid.org/0000-0001-6746-5441
Dalmia, Sanjush http://orcid.org/0000-0003-0261-2951
McLennan Battleday, Finn
Rogers, Zoe
Absolom, Kate
Bekker, Hilary
Franks, Kevin
Brunelli, Alex
Velikova, Galina http://orcid.org/0000-0003-1899-5942
Funding for this research was provided by:
yorkshire cancer research (L-399)
Article History
Received: 30 July 2021
Accepted: 3 September 2021
First Online: 13 September 2021
Declarations
:
: Dr. Pompili reports personal fees from BARD, Astra Zeneca and Medela outside the submitted work. Dr. Brunelli reports personal fees from BARD, personal fees from Astra Zeneca, personal fees from Roche, personal fees from Medtronic and personal fees from Ethicon, outside the submitted work. Dr. Franks reports personal fees from Astra Zeneca, Roche, Boerhinger-Ingelheim, Bristol-Meyers-Squibb, Lilly, ELEKTA, ESMO and Takeda, outside the submitted work. Prof. Velikova reports personal fees from Roche, Eisai, Novartis and Seattle Genetics and roles as chair of the NCRI Living With and Beyond Cancer Group and board member of the EORTC. The remaining authors declare no conflicts of interest.
: This study has received ethical approval from The National Research Ethics Service Yorkshire and the Humber-Leeds East Committee—(REC Ref: 16/YH/0407). Two substantial amendments to this study were granted with no request of modifications. One amendment (Substantial Amendment 1, 18/04/17) was to send a letter with PIS and consent form to the patient before their clinical appointment and the second one (Substantial Amendment 3, 09/05/18) was to modify the end-of-study interview schedules.
: All participants provided written informed consent.